🟢 Taysha Gene Therapies is trading 6% up; no confirmed catalyst

Taysha Gene Therapies is trading at $4.17, up +5.96%, with no confirmed company-specific announcement explaining the October 20 move.

• Taysha’s investor-relations page lists an October 2 release as its latest press release.
• Recent coverage revisited TSHA-102 Rett syndrome trial data, including milestone gains in all 10 treated participants; this is prior clinical news, not a confirmed new catalyst.
• Biotech strength was reported on October 19, but there is no evidence linking a sector move to the October 20 gain.